NCT01496495View on ClinicalTrials.gov

A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes

PHASE1CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

December 31, 2014

Study Completion Date

March 18, 2015

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

ARRY-614, p38/Tie2 inhibitor; oral

Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule

Trial Locations (4)

30322

Emory University, Winship Cancer Institute, Atlanta

33612

Moffitt Cancer Center, Tampa

44195

Cleveland Clinic, Cleveland

77030

MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

Array Biopharma, now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT01496495 - A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes | Biotech Hunter | Biotech Hunter